Evaluation of five susceptibility test methods for detection of tobramycin resistance in a cluster of epidemiologically related Acinetobacter baumannii isolates

Journal of Clinical Microbiology

Volumn 51, Issue 8, 2013, Pages 2535-2540

  Moodley, V Mischka ^a,b   Oliver, Stephen P ^a,b   Shankland, Iva ^b   Elisha, B Gay ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN;

AAC(3) IIA GENE; ACINETOBACTER BAUMANNII; AGAR DILUTION; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; EPSILOMETER TEST; GENE CLUSTER; HUMAN; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DIAGNOSTIC ERRORS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; SOUTH AFRICA; TOBRAMYCIN;

EID: 84880585839     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03250-12     Document Type: Article

References (31)

1. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gramnegative bacilli. Clin. Infect. Dis. 41:848-854.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.
3. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. 1998. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J. Clin. Microbiol. 36:1938-1941.
4. Musa EK, Desai N, Casewell MW. 1990. The survival of Acinetobacter calcoaceticus inoculated on fingertips and on formica. J. Hosp. Infect. 15: 219-227.
5. Talbot GH, Bradley J, Edwards JE, Jr, Gilbert D, Scheld M, Bartlett JG. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
6. Apisarnthanarak A, Mundy LM. 2009. Mortality associated with Pandrug-resistant Acinetobacter baumannii infections in Thailand. Am. J. Infect. Control 37:519-520.
7. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, Mussap M, Artioli S, Ansaldi F, Durando P, Orengo G, Bobbio Pallavicini F, Viscoli C. 2008. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 61:417-420.
8. Cascio A, Conti A, Sinardi L, Iaria C, Angileri FF, Stassi G, David T, Versaci A, Iaria M, David A. 2010. Post-neurosurgical multidrugresistant Acinetobacter baumannii meningitis treated successfully with intrathecal colistin. A new case and a systematic review of the literature. Int. J. Infect. Dis. 14:e572-e579. doi:10.1016/j.ijid.2009.06.032.
9. Coelho J, Woodford N, Turton J, Livermore DM. 2004. Multiresistant acinetobacter in the UK: how big a threat? J. Hosp. Infect. 58:167-169.
10. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. 2008. Pan-drug resistant Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumanii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents 32:450-454.
11. Akers KS, Chaney C, Barsoumian A, Beckius M, Zera W, Yu X, Guymon C, Keen EF III, Robinson BJ, Mende K, Murray CK. 2010. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J. Clin. Microbiol. 48:1132-1138.
12. Silbert S, Pfaller MA, Hollis RJ, Barth AL, Sader HS. 2004. Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect. Control Hosp. Epidemiol. 25:847-851.
13. Snyder JW, Munier GK, Johnson CL. 2008. Direct comparison of the BD phoenix system with the Microscan Walk Away system for the identification and antimicrobial susceptibility testing of Enterobacteriaceae and nonfermentative Gram-negative organisms. J. Clin. Microbiol. 46:2327-2333.
14. Tenover FC, Mizukii TS, Carlson LG. 1990. Evaluation of auto SCANW/A automated microbiology system for the identification of nonglucose-fermenting gram-negative bacilli. J. Clin. Microbiol. 28:1628-1634.
15. Kulah C, Aktas E, Comert F, Ozlu N, Akyar I, Ankarali H. 2009. Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan Walk Away, Vitek2); high error rates with Microscan Walk Away. BMC Infect. Dis. 9:30. doi:10.1186/1471-2334-9-30.
16. Visser MR, Bogaards L, Rozenber-Arska M, Verhoef J. 1992. Comparison of the auto SCAN W/A and Vitek Automicrobic systems for identification and susceptibility testing of bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 11:979-984.
17. Washington JA. 1993. Rapid antimicrobial susceptibility testing: technical and clinical considerations. Clin. Microbiol. Newsl. 15:153-155.
18. White RL, Kays MB, Friedrich LV, Brown EW, Koonce JR. 1991. Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels. J. Clin. Microbiol. 29:398-400.
19. Jung S, Yu JK, Shin SH, Park KG, Jekarl DW, Han K, Park YJ. 2010. False susceptibility to amikacin by the Vitek2 in Acinetobacter baumannii harboring armA. Ann. Clin. Lab. Sci. 40:167-171.
20. Juretschko S, LaBombardi VL, Learner SA, Schreckenberger PC, and the Pseudomonas Study Group AST. 2007. Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek and Vitek2). J. Clin. Microbiol. 45:1339-1342.
21. Jacobson RK. 2007. MSc thesis. Association of IS1133 with an aminoglycoside resistance gene, aacC2a, in Acinetobacter baumannii isolates. University of Cape Town, Cape Town, South Africa.
22. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Clinical Laboratory Standards Institute. 2006. Performance standards for antimicrobial disk susceptibility tests, 9th ed. Approved standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Barry J, Brown A, Ensor V, Lakhani U, Petts D, Warren C, Winstanley T. 2003. Comparative evaluation of the Vitek2 Advanced Expert System (AES) in five UK hospitals. J. Antimicrob. Chemother. 51:1191-1202.
25. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Seifert H, Dolzani L, Bressan R, van der Reijden T, van Streijen B, Stefanik D, Heersma H, Dijkshoorn L. 2005. Standardisation and interlaboratory reproducibility assessment of pulsed field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J. Clin. Microbiol. 43: 4328-4335.
27. Clinical and Laboratory Standards Institute. 2001. Development of in vitro susceptibility testing criteria and quality control parameters, 2nd ed. Approved guideline M23-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
28. Seward RJ, Lambert T, Towner KJ. 1998. Molecular epidemiology of aminoglycoside resistance in Acinetobacter spp. J. Med. Microbiol. 47: 455-462.
29. Shaw KJ, Rather PN, Hare RS, Miller GH. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57:138-163.
30. Magnet S, Courvalin P, Lambert T. 1999. Activation of the cryptic aac(6=)-Iy aminoglycoside resistance gene of Salmonella by a chromosomal deletion generating a transcriptional fusion. J. Bacteriol. 181:6650-6655.
31. Magnet S, Blanchard JS. 2005. Molecular insights into aminoglycoside action and resistance. Chem. Rev. 105:477-498.